Reviva Pharmaceuticals Aims for Q2 2026 NDA Submission for Schizophrenia Treatment

Reviva Pharmaceuticals is advancing its schizophrenia treatment, brilaroxazine, towards regulatory approval with a potential NDA submission by Q2 2026. The company faces significant financial challenges, with negative earnings growth and a low Piotroski F-Score. Despite these challenges, Reviva has a robust clinical and non-clinical data package and hopes that brilaroxazine's unique clinical benefits will enhance treatment outcomes for schizophrenia patients globally.